A reproductive subtype of depression: Conceptualizing models and moving toward etiology

Harvard Review of Psychiatry

Volumn 17, Issue 2, 2009, Pages 72-86

  Payne, Jennifer L ^a   Palmer, Jennifer Teitelbaum ^a   Joffe, Hadine ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Estrogen; Major depression; Neurosteroids; Perimenopause; Postpartum; Premenstrual; Reproductive; Serotonin

Indexed keywords

ALPRAZOLAM; CONJUGATED ESTROGEN; DROSPIRENONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; PROGESTERONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; GLUCOCORTICOID;

CLIMACTERIUM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ESTROGEN THERAPY; GENETICS; HORMONE BLOOD LEVEL; HUMAN; MAJOR DEPRESSION; MEDLINE; MENARCHE; MENOPAUSE; MENSTRUAL CYCLE; MENTAL HEALTH; POSITRON EMISSION TOMOGRAPHY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PUERPERAL DEPRESSION; PUERPERIUM; REVIEW; RISK REDUCTION; SEROTONINERGIC SYSTEM; WOMEN'S HEALTH; ADULT; FEMALE; METABOLISM; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; PSYCHOLOGICAL ASPECT;

ADULT; DEPRESSIVE DISORDER, MAJOR; ESTROGENS; FEMALE; GLUCOCORTICOIDS; HUMANS; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; POSTPARTUM PERIOD; PREMENOPAUSE; SEROTONIN;

EID: 68549111041     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220902899706     Document Type: Review

References (126)

1. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. JAffect Disord 1993;29:85-96.
2. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-132
3. Bailey JW, Cohen LS. Prevalence of mood and anxiety disorders in women who seek treatment for premenstrual syndrome. J Womens Health Gend Based Med 1999;8:1181-1184
4. Rich-Edwards JW, Kleinman K, Abrams A, et al. Sociodemographic predictors of antenatal and postpartum depressive symptoms among women in a medical group practice. J Epidemiol Community Health 2006;60:221-227
5. Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 2004;161:2238-2244
6. Schmidt PJ, Roca CA, Rubinow DR. Clinical evaluation in studies of perimenopausal women: position paper. Psychopharmacol Bull 1998;34:309-311
7. Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol Psychiatry 1998;44:798-811.
8. Stewart DE, Boydell KM. Psychologic distress during menopause: associations across the reproductive life cycle. Int J Psychiatry Med 1993;23:157-162
9. Chuong CJ, Burgos DM. Medical history in women with premenstrual syndrome. J Psychosom Obstet Gynaecol 1995;16:21-27
10. Morse CA, Dudley E, Guthrie J, Dennerstein L. Relationships between premenstrual complaints and perimenopausal experiences. J Psychosom Obstet Gynaecol 1998;19:182-191
11. Gregory RJ, Masand PS, Yohai NH. Depression across the reproductive life cycle: correlations between events. Prim Care Companion J Clin Psychiatry 2000;2:127-129
12. Binfa L, Castelo-Branco C, Blumel JE, et al. Influence of psycho-social factors on climacteric symptoms. Maturitas 2004;48:425-431
13. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70.
14. Aydin N, Inandi T, Karabulut N. Depression and associated factors among womenwithin their first postnatal year in Erzurum province in eastern Turkey.Women Health 2005;41:1-12.
15. Bloch M, Rotenberg N, Koren D, Klein E. Risk factors associated with the development of postpartum mood disorders. J Affect Disord 2005;88:9-18.
16. Bloch M, Rotenberg N, Koren D, Klein E. Risk factors for early postpartum depressive symptoms. Gen Hosp Psychiatry 2006;28:3-8.
17. Richards M, Rubinow DR, Daly RC, Schmidt PJ. Premenstrual symptoms and perimenopausal depression. Am J Psychiatry 2006;163:133-137
18. Haywood A, Slade P, King H. Is there evidence of an association between postnatal distress and premenstrual symptoms? J Affect Disord 2007;99:241-245
19. Payne JL, Roy PS, Murphy-Eberenz K, et al. Reproductive cycle-associated mood symptoms in women withmajor depression and bipolar disorder. J Affect Disord 2007;99:221-229
20. Steinberg EM, Rubinow DR, Bartko JJ, et al. A cross-sectional evaluation of perimenopausal depression. J Clin Psychiatry 2008;69:973-980
21. Rubinow DR, Roy-Byrne P, Hoban MC, Gold PW, Post RM. Prospective assessment of menstrually related mood disorders. Am J Psychiatry 1984;141:684-686
22. Halbreich U, Endicott J. Methodological issues in studies of premenstrual changes. Psychoneuroendocrinology 1985;10:15-32.
23. Ainscough CE. Premenstrual emotional changes a prospective study of symptomatology in normal women. J Psychosom Res 1990;34:35-45.
24. Cooper PJ, Murray L. Course and recurrence of postnatal depression. Evidence for the specificity of the diagnostic concept. Br J Psychiatry 1995;166:191-195
25. Forty L, Jones L, Macgregor S, et al. Familiality of postpartum depression in unipolar disorder: results of a family study. Am J Psychiatry 2006;163:1549-1553
26. Murphy-Eberenz K, Zandi PP, March D, et al. Is perinatal depression familial? J Affect Disord 2006;90:49-55.
27. Widholm O, Kantero RL. A statistical analysis of the menstrual patterns of 8,000 Finnish girls and their mothers. Acta Obstet Gynecol Scand Suppl 1971;14:suppl 14:1-36.
28. Dalton K, Dalton ME, Guthrie K. Incidence of the premenstrual syndrome in twins. Br Med J (Clin Res Ed) 1987;295:1027-1028
29. Kendler KS, Silberg JL, Neale MC, Kessler RC, Heath AC, Eaves LJ. Genetic and environmental factors in the aetiology of menstrual, premenstrual and neurotic symptoms: a population-based twin study. Psychol Med 1992;22:85-100.
30. Kendler KS, Karkowski LM, Corey LA, Neale MC. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998;155:1234-1240
31. Condon JT. The premenstrual syndrome: a twin study. Br J Psychiatry 1993;162:481-486
32. Van Den Akker OB, Eves FF, Stein GS, Murray RM. Genetic and environmental factors in premenstrual symptom reporting and its relationship to depression and a general neuroticism trait. J Psychosom Res 1995;39:477-487
33. Treloar SA, Martin NG, Bucholz KK, Madden PA, Heath AC. Genetic influences on post-natal depressive symptoms: findings from an Australian twin sample. Psychol Med 1999;29:645-654
34. Glick H, Endicott J, Nee J. Premenstrual changes: are they familial? Acta Psychiatr Scand 1993;88:149-155
35. Van Den Akker OB, Stein GS, Neale MC, Murray RM. Genetic and environmental variation in menstrual cycle: histories of two British twin samples. Acta Genet Med Gemellol (Roma) 1987;36:541-548
36. Huo L, Straub RE, Roca C, et al. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 2007;62:925-933
37. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63:375-382
38. Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 2000;157:924-930
39. Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry 2008;65:805-815
40. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry 2006;63:385-390
41. Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). J Affect Disord 2007;103:267-272
42. Bebbington P, Dunn G, Jenkins R, et al. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Int Rev Psychiatry 2003;15:74-83.
43. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry 1997;58 suppl 15:19-25.
44. Rubinow DR, Schmidt PJ, Roca CA. Hormone measures in reproductive endocrine-related mood disorders: diagnostic issues. Psychopharmacol Bull 1998;34:289-290
45. Wieck A. Endocrine aspects of postnatal mental disorders. Baillieres Clin Obstet Gynaecol 1989;3:857-877
46. Wisner KL, Stowe ZN. Psychobiology of postpartum mood disorders. Semin Reprod Endocrinol 1997;15:77-89.
47. Nott PN, Franklin M, Armitage C, Gelder MG. Hormonal changes and mood in the puerperium. Br J Psychiatry 1976;128:379-383
48. O'Hara MW, Schlechte JA, Lewis DA, Wright EJ. Prospective study of postpartum blues. Biologic and psychosocial factors. Arch Gen Psychiatry 1991;48:801-806
49. Barrett-Connor E, von MD, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 1999;47:685-691
50. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998;338:209-216
51. Daly RC, Danaceau MA, Rubinow DR, Schmidt PJ. Concordant restoration of ovarian function and mood in perimenopausal depression. Am J Psychiatry 2003;160:1842-1846
52. Deecher D, Andree TH, Sloan D, Schechter LE. From menarche to menopause: exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology 2008;33:3-17.
53. Ellenbogen MA, Young SN, Dean P, Palmour RM, Benkelfat C. Mood response to acute tryptophan depletion in healthy volunteers: sex differences and temporal stability. Neuropsychopharmacology 1996;15:465-474
54. Booij L, Van der DW, Benkelfat C, et al. Predictors of mood response to acute tryptophan depletion. A reanalysis. Neuropsychopharmacology 2002;27:852-861
55. Moreno FA, McGahuey CA, Freeman MP, Delgado PL. Sex differences in depressive response during monoamine depletions in remitted depressive subjects. J Clin Psychiatry 2006;67:1618-1623
56. Bancroft J, Cook A, Davidson D, Bennie J, Goodwin G. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psychol Med 1991;21:305-312
57. Bond AJ,Wingrove J, Critchlow DG. Tryptophan depletion increases aggression in women during the premenstrual phase. Psychopharmacology (Berl) 2001;156:477-480
58. Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 1994;32:37-44.
59. Epperson CN, Amin Z, Naftolin F, et al. The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings. J Psychopharmacol 2007;21:414-420
60. Jovanovic H, Cerin A, Karlsson P, Lundberg J, Halldin C, Nordstrom AL. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 2006;148:185-193
61. Moses EL, DrevetsWC, Smith G, et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiatry 2000;48:854-860
62. Schmidt PJ, Rubinow DR. Reproductive ageing, sex steroids and depression. J Br Menopause Soc 2006;12:178-185
63. Pecins-Thompson M, Brown NA, Bethea CL. Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques. Brain Res Mol Brain Res 1998;53:120-129
64. Clarke WP, Maayani S. Estrogen effects on 5-HT1A receptors in hippocampal membranes from ovariectomized rats: functional and binding studies. Brain Res 1990;518:287-291
65. Okada M, Hayashi N, Kometani M, Nakao K, Inukai T. Influences of ovariectomy and continuous replacement of 17betaestradiol on the tail skin temperature and behavior in the forced swimming test in rats. Jpn J Pharmacol 1997;73:93-96
66. Lerch-Haner JK, Frierson D, Crawford LK, Beck SG, Deneris ES. Serotonergic transcriptional programming determines maternal behavior and offspring survival. Nat Neurosci 2008;11:1001-1003
67. Watson NR, Studd JW, Savvas M, Garnett T, Baber RJ. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989;2:730-732
68. Dhar V, Murphy BE. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology 1990;15:489-493
69. Watson NR, Studd JW, Savvas M, Baber RJ. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol Endocrinol 1990;4:99-107.
70. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995;274:51-57
71. Smith RN, Studd JW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995;102:475-484
72. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001;10:561-569
73. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-421
74. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson- Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501.
75. Joffe H, Petrillo LF, Viguera AC, et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. J Clin Psychiatry 2007;68:1954-1962
76. Young EA, Kornstein SG, Harvey AT, et al. Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology 2007;32:843-853
77. Sichel DA, Cohen LS, Robertson LM, Ruttenberg A, Rosenbaum JF. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry 1995;38:814-818
78. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996;347:930-933
79. Ahokas A, Aito M, Rimon R. Positive treatment effect of estradiol in postpartum psychosis: a pilot study. J Clin Psychiatry 2000;61:166-169
80. Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen defi- ciency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. J Clin Psychiatry 2001;62:332-336
81. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord 1999;55:11-17
82. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-420
83. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebocontrolled trial. Arch Gen Psychiatry 2001;58:529-534
84. Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs 2007;67:1749-1765
85. Freeman EW. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. Eur J Contracept Reprod Health Care 2002;7 suppl 3:27-34.
86. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998;59:76-80.
87. Freeman EW, Borisute H, Deal L, Smith L, Grubb GS, Constantine GD. A continuous-use regimen of levonorgestrel/ ethinyl estradiol significantly alleviates cyclerelated symptoms: results of a phase 3 study. Fertil Steril 2005;84(suppl 1):S25.
88. Halbreich U, O'Brien PM, Eriksson E, Backstrom T, Yonkers KA, FreemanEW. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? CNS Drugs 2006;20:523-547
89. Freeman EW. Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder. Curr Psychiatry Rep 2002;4:435-440
90. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006;74:100-103
91. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006;195:1311-1319
92. Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL, Cohen LS. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 2003;64:473-479
93. Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 2006;13:780-786
94. Joffe H, Groninger H, Soares CN, Nonacs R, Cohen LS. An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. JWomens Health Gend Based Med 2001;10:999-1004.
95. Morrison MF, Kallan MJ, Ten HT, Katz I, Tweedy K, Battistini M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry 2004;55:406-412
96. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P,Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002;287:591-597
97. Wisner KL, Hanusa BH, Perel JM, et al. Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol 2006;26:353-360
98. Raskin A. Age-sex differences in response to antidepressant drugs. J Nerv Ment Dis 1974;159:120-130
99. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000;157:1445-1452
100. Baca E, Garcia-Garcia M, Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:57-65.
101. Thase ME, Entsuah R, Cantillon M, Kornstein SG. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 2005;14:609-616
102. Pinto-Meza A, Usall J, Serrano-Blanco A, Suarez D, Haro JM. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? J Affect Disord 2006;93:53-60.
103. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997;58:399-402.
104. Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997;33: 771-774 (Pubitemid 28128134)
105. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998;18: 390-398
106. Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999;8:328-332
107. Cohen LS, Miner C, Brown EW, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebocontrolled, clinical trial using computerized diaries. Obstet Gynecol 2002;100:435-444 (Pubitemid 35246128)
108. Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, doubleblind, placebo-controlled clinical trial. Clin Ther 2002;24:417-433 (Pubitemid 34275863)
109. Steiner M, Hirschberg AL, Bergeron R, Holland F, Gee MD, Van EE. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005;193:352-360
110. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000;157:1423-1428
111. Tollefson GD, Holman SL. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 1994;9: 245-250
112. Freeman EW, Rickels K, Sondheimer SJ, Wittmaack FM. Sertraline versus desipramine in the treatment of premenstrual syndrome: an open-label trial. J Clin Psychiatry 1996;57:7-11.
113. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999;56:932-939
114. Wisner KL, Perel JM, Peindl KS, Hanusa BH, Piontek CM, Findling RL. Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry 2004;161:1290-1292
115. Wisner KL, Perel JM, Peindl KS, Hanusa BH, Findling RL, Rapport D. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatry 2001;62:82-86
116. Longone P, Rupprecht R, Manieri GA, Bernardi G, Romeo E, Pasini A. The complex roles of neurosteroids in depression and anxiety disorders. Neurochem Int 2008;52:596-601.
117. Romeo E, Strohle A, Spalletta G, et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998;155:910-913
118. Strohle A, Romeo E, Hermann B, et al. Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry 1999;45:274-277
119. Strohle A, Pasini A, Romeo E, et al. Fluoxetine decreases concentrations of 3 alpha, 5 alpha-tetrahydrodeoxycorticosterone (THDOC) inmajor depression. J Psychiatr Res 2000;34:183-186
120. Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patientswith unipolarmajor depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci U S A 1998;95:3239-3244
121. Girdler SS, Klatzkin R. Neurosteroids in the context of stress: implications for depressive disorders. Pharmacol Ther 2007;116:125-139
122. Epperson CN, deWit H, Krystal JH. Advances in the translational neuroscience of neurosteroids. Psychopharmacology (Berl) 2006;186:265-266
123. Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl) 2006;186:362-372
124. Griffin LD,Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A 1999;96:13512-13517
125. van BF, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology (Berl) 2003;165:97-110.
126. Maguire J, Mody I. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron 2008;59:207-213